On March 28, 2024 Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, reported it will present data for its oncology candidate NT219, a first-in-class small molecule, dual-inhibitor of IRS 1/2 and STAT3, in two poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting which takes place April 5-11, 2024, in San Diego, California (Press release, Purple Biotech, MAR 28, 2024, View Source [SID1234641575]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The growing body of clinical, biomarker, and preclinical data for NT219 demonstrate its potential not only in the lead indication of recurrent/metastatic squamous cell carcinoma of the head and neck, but also in other solid-tumor cancers. These publications at AACR (Free AACR Whitepaper) 2024 are a result of the progress made last year both in clinical and preclinical work bringing out NT219’s attributes," stated Gil Efron, Chief Executive Officer of Purple Biotech. "We look forward to leveraging these data as we move forward with the clinical evaluation of NT219."
Dr Hadas Reuveni, VP Research and Development at Purple Biotech, added, "At AACR (Free AACR Whitepaper) 2024 we will present new data related to NT219. We show for the first time the potential of NT219 to effectively suppress cancer stem cells (CSC), a critical cell population for tumor propagation, characterized by self-renewal and multipotency, and known to promote resistance and tumor recurrence. In addition, synergistic effect of NT219 and mKRAS inhibitors is demonstrated, suggesting a novel mechanism to combat resistance to both KRASG12C and KRAS KRASG12D inhibitors in lung cancer and pancreatic cancers, respectively, both aggressive diseases with unmet medical need. In another presentation, we show the results of translational research in our Phase 1 study, suggesting activated IGF1R and STAT3 as potential biomarkers for the treatment with NT219. We will further evaluate these biomarkers in the next study."
Poster Details:
Title: NT219, a dual inhibitor of IRS1/2 and STAT3, suppresses cancer stem cell mediated resistance to KRASG12C and KRASG12D inhibitors in solid tumors
Session Category: Experimental and Molecular Therapeutics
Session Title: Drug Resistance 2: Ras GTPase
Session Date and Time: Monday Apr 8, 2024, 9:00 AM – 12:30 PM PST
Published Abstract Number: 1939
Title: Early activity and biomarker evaluation of NT219 in combination with cetuximab in a Phase 1/2 study of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Session Category: Clinical Research
Session Title: Predictive Biomarkers 4
Session Date and Time: Tuesday Apr 9, 2024, 9:00 AM – 12:30 PM PST
Published Abstract Number: 5181
The abstracts are available on the AACR (Free AACR Whitepaper) Online Program Planner and were published in the online-only Proceedings supplement to the AACR (Free AACR Whitepaper) journal Cancer Research. The presented posters will be available on the Publications section of Purple Biotech’s website, following their presentations at the conference.